Hisamitsu Pharmaceutical Co., Inc. , headquartered in Saga and Tokyo, Japan is a pharmaceutical company that develops and markets prescription and over-the-counter drug products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialized in transdermal drug delivery system technology since the introduction of its original line of patches in 1903. Its Salonpas brand of products are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape line of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eye drops for general application and the Lifecella Face Mask, a skin-care product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration . Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Hisamitsu Pharmaceutical | Date: 2017-08-30

The present invention provides a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof:_(1-6) alkyl group optionally substituted with one or more hydroxyl groups, a C_(1-6) alkoxy group, or a cyano group.


Patent
Hisamitsu Pharmaceutical | Date: 2017-07-19

The present invention provides a microneedle device comprising: a substrate; a microneedle disposed on the substrate; and a coating layer formed on the microneedle; wherein the coating layer comprises a physiologically active substance, arginine, and glycerin.


Patent
Hisamitsu Pharmaceutical and ASKA Pharmaceutical Co. | Date: 2017-09-06

The present invention provides a microneedles device comprising: a substrate; a microneedle disposed on the substrate; and a coating layer formed on the microneedle; in which the coating layer comprises a recombinant follicle-stimulating hormone, arginine, and glycerin, in the coating layer, the mass of arginine is 0.07 to 0.75-fold of the mass of the recombinant follicle-stimulating hormone and the mass of glycerin is 0.1 to 2.75-fold of the mass of the recombinant follicle-stimulating hormone.


Patent
Hisamitsu Pharmaceutical | Date: 2015-10-13

A patch including: a support; and an adhesive layer disposed on at least one surface of the support, in which the adhesive layer includes: at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof; a higher aliphatic alcohol; and a non-cross-linking polyvinylpyrrolidone that does not contain vinyl acetate as a constituent monomer thereof.


Patent
Hisamitsu Pharmaceutical | Date: 2017-01-04

The invention provides a gel patch comprising a support and an adhesive layer on the support, wherein the adhesive layer comprises 1.5 to 2.5 mass% of ketoprofen, 1.5 to 2.5 mass% of 4-tert-butyl-4-methoxydibenzoylmethane and 12 to 18 mass% of propylene glycol, based on the total mass of the adhesive layer.


Patent
Hisamitsu Pharmaceutical | Date: 2017-01-04

A microneedle sheet according to an embodiment includes a plurality of microneedles formed on a sheet generally along a principal surface of the sheet. The material of the microneedles is selected from among hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl alcohol, and a graft copolymer of polyvinyl alcohol and polyethylene glycol. The microneedles are raised from the principal surface by bending the sheet, and the raised microneedles pierce skin.


Patent
Hisamitsu Pharmaceutical | Date: 2015-02-19

A microneedle sheet according to an embodiment includes a plurality of microneedles formed on a sheet generally along a principal surface of the sheet. The material of the microneedles is selected from among hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl alcohol, and a graft copolymer of polyvinyl alcohol and polyethylene glycol. The microneedles are raised from the principal surface by bending the sheet, and the raised microneedles pierce skin.


Patent
Hisamitsu Pharmaceutical | Date: 2017-08-23

A patch including: a support; and an adhesive layer disposed on at least one surface of the support, in which the adhesive layer includes: at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof; a higher aliphatic alcohol; and a non-cross-linking polyvinylpyrrolidone that does not contain vinyl acetate as a constituent monomer thereof.


Patent
Hisamitsu Pharmaceutical | Date: 2016-10-24

A method for producing a patch comprising a support layer and an adhesive agent layer comprises: a mixture preparation step of mixing asenapine or a pharmaceutically acceptable salt thereof with sodium acetate whose particle diameter D_(50 )at a cumulative volume of 50% in a particle diameter distribution is 40 to 1000 m, in such a manner that the sodium acetate and sodium diacetate generated from the sodium acetate have a particle diameter D_(50 )of 10 m or smaller, thereby obtaining a mixture containing the sodium diacetate and the asenapine or pharmaceutically acceptable salt; and an adhesive-agent-layer formation step of forming the adhesive agent layer comprising the sodium diacetate, the asenapine or pharmaceutically acceptable salt, and a pressure-sensitive adhesive base agent, by using an adhesive agent layer composition obtained by mixing the mixture with the pressure-sensitive adhesive base agent.


Patent
Hisamitsu Pharmaceutical | Date: 2017-03-09

A patch for administering asenapine includes a support layer, and an adhesive agent layer formed on the support layer and including an adhesive base agent and asenapine and/or a pharmaceutically acceptable salt thereof. The adhesive base agent has a content in a range of 10 to 90% by mass in the adhesive agent layer and includes a natural rubber, polyisobutylene, an alkyl vinyl ether(co)polymer, polyisoprene, polybutadiene, a styrene-butadiene copolymer, a styrene-isoprene copolymer, a styrene-isoprene-styrene block copolymer, or a combination thereof. When a content of the asenapine and/or pharmaceutically acceptable salt thereof in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC_(2-120 )for a period starting from the time when the patch is brought into contact with a skin for 24 hours is 27,000 pghr/mL or more, and an AUC_(2-120 )of an asenapine metabolite is 20% or less of the AUC_(2-120 )of the free asenapine.

Loading Hisamitsu Pharmaceutical collaborators
Loading Hisamitsu Pharmaceutical collaborators